Exploring the therapeutic role of probiotics and prebiotics in mitigating diseases associated with advanced glycation end products.

IF 3.2 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Applied Microbiology Pub Date : 2025-10-06 DOI:10.1093/jambio/lxaf233

Haiqing Sun, Zhenjiang Liu, Xin Li, Dongxu Wen, Bin Li, Xiaodan Huang

{"title":"Exploring the therapeutic role of probiotics and prebiotics in mitigating diseases associated with advanced glycation end products.","authors":"Haiqing Sun, Zhenjiang Liu, Xin Li, Dongxu Wen, Bin Li, Xiaodan Huang","doi":"10.1093/jambio/lxaf233","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced glycation end products (AGEs) are a class of compounds generated when reducing sugars interact with proteins, lipids, and other molecular structures. Excessive accumulation of AGEs in the body accelerates aging and contributes to various chronic conditions, including diabetes, neurodegenerative diseases, cardiovascular diseases, and inflammatory bowel diseases. Despite growing interest in strategies to prevent glycation damage, effective interventions to combat AGE-related diseases remain limited. This review examines the role of AGEs in disease pathology and evaluates strategies to mitigate their harmful effects. It further summarizes natural products and pharmaceutical agents currently used for anti-glycation purposes, along with their underlying mechanisms. Additionally, we explore the promising therapeutic potential of probiotics and prebiotics in protecting against AGE-related diseases, highlighting research evidence demonstrating their ability to reduce AGE accumulation and inhibit their formation. This review aims to inform the development of more effective glycation inhibitors and addresses the pressing gap in current research regarding targeted AGEs interventions.</p>","PeriodicalId":15036,"journal":{"name":"Journal of Applied Microbiology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/jambio/lxaf233","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Advanced glycation end products (AGEs) are a class of compounds generated when reducing sugars interact with proteins, lipids, and other molecular structures. Excessive accumulation of AGEs in the body accelerates aging and contributes to various chronic conditions, including diabetes, neurodegenerative diseases, cardiovascular diseases, and inflammatory bowel diseases. Despite growing interest in strategies to prevent glycation damage, effective interventions to combat AGE-related diseases remain limited. This review examines the role of AGEs in disease pathology and evaluates strategies to mitigate their harmful effects. It further summarizes natural products and pharmaceutical agents currently used for anti-glycation purposes, along with their underlying mechanisms. Additionally, we explore the promising therapeutic potential of probiotics and prebiotics in protecting against AGE-related diseases, highlighting research evidence demonstrating their ability to reduce AGE accumulation and inhibit their formation. This review aims to inform the development of more effective glycation inhibitors and addresses the pressing gap in current research regarding targeted AGEs interventions.

查看原文本刊更多论文

探索益生菌和益生元在缓解晚期糖基化终产物相关疾病中的治疗作用。

晚期糖基化终产物（AGEs）是还原糖与蛋白质、脂质和其他分子结构相互作用时产生的一类化合物。AGEs在体内的过度积累会加速衰老，并导致各种慢性疾病，包括糖尿病、神经退行性疾病、心血管疾病和炎症性肠病。尽管人们对预防糖基化损伤的策略越来越感兴趣，但对抗年龄相关疾病的有效干预措施仍然有限。本文综述了AGEs在疾病病理中的作用，并评估了减轻其有害影响的策略。它进一步总结了目前用于抗糖化目的的天然产物和药物制剂，以及它们的潜在机制。此外，我们还探讨了益生菌和益生元在预防年龄相关疾病方面的治疗潜力，重点介绍了研究证据，证明它们能够减少年龄积累并抑制其形成。本综述旨在为更有效的糖基化抑制剂的开发提供信息，并解决当前关于靶向AGEs干预研究中的紧迫空白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Applied Microbiology 生物-生物工程与应用微生物

CiteScore

7.30

自引率

2.50%

发文量

427

审稿时长

2.7 months

期刊介绍： Journal of & Letters in Applied Microbiology are two of the flagship research journals of the Society for Applied Microbiology (SfAM). For more than 75 years they have been publishing top quality research and reviews in the broad field of applied microbiology. The journals are provided to all SfAM members as well as having a global online readership totalling more than 500,000 downloads per year in more than 200 countries. Submitting authors can expect fast decision and publication times, averaging 33 days to first decision and 34 days from acceptance to online publication. There are no page charges.